Adverse events, need for hospitalization and systemic immunosuppression in very older patients (over 80 years) treated with anti-PD-1 for metastatic melanoma

J Geriatr Oncol. 2020 Nov;11(8):1340-1343. doi: 10.1016/j.jgo.2020.03.003. Epub 2020 Mar 18.
No abstract available

Keywords: Adverse events; Anti-PD1; Melanoma; Nivolumab; Older; Older adults; Pembrolizumab.

Publication types

  • Letter

MeSH terms

  • Hospitalization
  • Humans
  • Immunosuppression Therapy
  • Ipilimumab
  • Melanoma* / drug therapy
  • Skin Neoplasms* / drug therapy

Substances

  • Ipilimumab